The observed effects after direct disruption of the YAP/TAZ–TEAD transcriptional complex in mesothelioma and Hippo-mutated tumor cells bearing NF2 loss-of-function mutations or YAP–TAZ fusions were instrumental in establishing a clinical rationale for an ongoing first-in-human study (NCT04857372) of the oral compound IAG933 in these types of solid tumors. This evidence concerns the gene YAP1 and neoplasm.